Jeffrey Dome, MD, PhD Division Chief, Hematology, Oncology

Bio

Biography

Jeffrey Dome, MD, PhD, is chief of the Division of Oncology and the Division of Hematology. Dr. Dome specializes in pediatric solid tumors, with an emphasis on Wilms tumors and other pediatric kidney tumors. As chair of the Renal Tumor Committee for the Children's Oncology Group (COG), Dr. Dome oversees clinical trials for Wilms tumors and other childhood kidney cancers in more than 200 children's hospitals. He has authored more than 30 articles and textbook chapters on pediatric kidney tumors.

Dr. Dome lives in Maryland with his wife, son, and daughter.

Education & Training

Education & Training

  • Fellowship Program, Pediatric Hematology/Oncology, 1997
    Johns Hopkins Hospital
  • Residency Program, Pediatrics, 1994
    Yale-New Haven Hospital
  • Internship Program, Pediatrics, 1992
    Yale-New Haven Hospital
  • MD, 1991
    University of Pennsylvania School of Medicine
  • BA, 1987
    University of Pennsylvania
Patient Stories

Patient Stories: Jeffrey Dome

Alexx's Story

After a battle with cancer, her 16th birthday is even sweeter.

Patient story

Staci's Story

"As a parent/caretaker, you want to fight with every ounce of fight that you have. It's normal and necessary to help you feel like you are fighting right along with your precious baby."

Patient story

Lillie's Story

"The following days, more testing followed until we got the news- the words no parent ever wants to hear- our baby girl had cancer."

Patient story

Ethan's Story

"Hearing the words 'Your child has cancer' are some of the most difficult words to hear, but I want to tell you that you will get through this."

News

News

Research & Publications

Research & Publications

Age at diagnosis as a prognostic factor for rhabdoid tumor of the kidney A report from the National Wilms Tumor Study Group

(2005) Journal of Clinical Oncology

Disappearance of the Telomere dysfunctioninduced stress response in fully senescent cells

(2004) Cancer Research

High telomerase RNA expression is an adverse prognostic factor for favorable histology Wilms tumor

(2005) Journal of Clinical Oncology

Improved survival for patients with recurrent Wilms tumor

(2002) Journal of Pediatric Hematology Oncology

Recent advances in Wilms tumor genetics

(2002) Current Opinion in Pediatrics

Telomerase expression predicts unfavorable outcome in osteosarcoma

(2004) Journal of Clinical Oncology

Telomere biology of pediatric cancer

(2007) Cancer Investigation

The feasibility and outcome of nephronsparing surgery for children with bilateral Wilms tumor The St Jude Childrens Research Hospital Experience 19992006

(2008) Cancer

Topotecan is active against Wilms tumor Results of a multiinstitutional phase II study

(2007) Journal of Clinical Oncology

Treatment of Anaplastic Histology Wilms Tumor Results from the Fifth National Wilms Tumor Study

(2006) Journal of Clinical Oncology

View publications on PubMed

Invest in future cures for some of life's most devastating diseases

See other ways to give

Keep in touch with Children's National by signing up for our newsletters.

Sign up now